Copyright © Inderes 2011 - present. All rights reserved.

Biohit

2,14 EUR +1,42%
4.677 investorer følger denne virksomhed

Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.

P/E (adj.) (24e)
16,92
EV/EBIT (adj.) (24e)
12,8
P/B (24e)
2,81
Udbytteafkast, % (24e)
-
Kursmål
2.70 EUR
Anbefaling
Akkumulér
Opdateret
8.8.2024
NASDAQ Helsinki
BIOBV
Daglig lav / høj pris
2,1 / 2,14 EUR
Markedsværdi
32,47 mio. EUR
Aktieomsætning
8,43 t EUR
Volumen
3,9 t
Business risk
Valuation risk
Current
Previous

Seneste analyser

Biohit: Growth measures taking effect
15.02.2024
Biohit: From basics to growth mode
20.12.2023
Biohit: Positive result from H1 test
10.08.2023

Extensive report

Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the report

Analytiker

Antti Siltanen
Antti Siltanen
Analytiker

Seneste videoer

Biohit: Preconditions for a turnaround
03.07.2023

Resultatopgørelse

20202021202220232024e2025e2026e2027e
Omsætning7,19,411,013,115,117,419,822,4
vækst-%-29,1 %31,4 %17,0 %19,2 %15,9 %15,3 %13,5 %13,0 %
EBITDA-1,20,51,62,12,42,63,44,0
EBIT (adj.)-3,2-1,51,11,82,02,32,83,3
EBIT-3,2-1,51,11,82,02,32,83,3
Overskud før skat-3,3-1,30,92,22,32,53,03,5
Netto indkomst-3,3-1,50,61,81,92,02,42,8
EPS (adj.)-0,22-0,100,040,120,130,130,160,18
vækst-%189,9 %9,2 %4,9 %20,9 %14,8 %
Udbytte0,000,000,000,000,000,000,030,06
Udbytte ratio18,7 %30,0 %

Lønsomhed og afkast på kapital

20202021202220232024e2025e2026e2027e
EBITDA-%-16,5 %5,4 %14,7 %16,1 %16,0 %14,9 %17,3 %18,0 %
EBIT-% (adj.)-44,6 %-15,8 %10,3 %13,4 %13,3 %12,9 %14,3 %14,7 %
EBIT-%-44,6 %-15,8 %10,3 %13,4 %13,3 %12,9 %14,3 %14,7 %
ROE-28,3 %-18,5 %8,0 %20,6 %18,3 %16,0 %16,5 %16,3 %
ROI-25,9 %-17,7 %14,3 %19,1 %19,3 %18,9 %20,6 %20,3 %

Værdiansættelse

20202021202220232024e2025e2026e2027e
Aktiekurs (EUR)2,481,841,571,922,142,142,142,14
Aktier15,015,015,015,115,115,115,115,1
Markedsværdi37,327,723,629,032,332,332,332,3
Enterprise value31,622,318,324,525,823,721,820,0
EV/S4,42,41,71,91,71,41,10,9
EV/EBITDA-44,011,411,710,79,16,45,0
EV/EBIT (adj.)--16,314,012,810,57,76,1
EV/EBIT--16,314,012,810,57,76,1
P/E (adj.)--39,316,616,916,113,311,6
P/E--39,316,616,916,113,311,6
P/B4,23,83,13,12,82,42,01,8
P/S5,23,02,22,22,11,91,61,4
Udbytteprocent1,4 %2,6 %
Equity ratio81,6 %76,7 %68,7 %73,1 %78,6 %84,3 %84,7 %84,9 %
Gearing ratio-64,7 %-72,4 %-69,8 %-47,6 %-57,3 %-64,1 %-66,1 %-67,8 %

Kvartalsdata

Q3/23Q4/232023Q1/24Q2/24Q3/24eQ4/24e2024eQ1/25e
Omsætning6,613,17,47,715,1
EBITDA0,42,11,51,02,4
EBIT0,31,81,30,82,0
Overskud før skat0,52,21,50,92,3
Netto indkomst0,51,81,30,71,9
Login in to make your own estimates and see other investors estimates.
ViserAlle indholdstyper
Biohit H1'24 preview: Opening of a new strategy period
Analytikerkommentar af
Antti Siltanen

Biohit H1'24 preview: Opening of a new strategy period

Biohit will release its H1 report on Wednesday, August 7 at 9:30 am EEST. We expect the company to continue healthy growth during the first six months of the new strategy period. We expect the result to be at the level of the comparison period, as growth investments increase costs.

Biohit
Analytikerkommentar af
Antti Siltanen

Biohit strengthens R&D

On Friday, Biohit announced that it will change its organization to strengthen the company’s strategic and operational performance of R&D.

Biohit

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Analytikerkommentar af
Antti Siltanen

Biohit's Q1 has gone according to plan

Biohit that reports semi-annually does not publish business reviews for Q1 and Q3 but the company reports on its progress in the CEO’s blog. According to the blog, the implementation of the new strategy 2024-2028 started in Q1 as planned and on schedule.

Biohit
Analyse af
Antti Siltanen

Biohit: Growth measures taking effect

Biohit’s H2 exceeded our expectations in terms of growth and earnings were in line with our forecasts. Revenue growth was supported by positive development in various products and markets.

Biohit
Analytikerkommentar af
Antti Siltanen

Biohit H2 on Wednesday: Groundwork for the new strategy period

We expect revenue of 5.9 MEUR and EBIT of 0.4 MEUR, driven by the improved efficiency in company operations and extensive utilization of growth drivers. We do not expect dividends as future growth investments require capital. In addition to the figures, we are interested in information on the sales of Gastropanel® products, and especially the new fingerprick test, and its outlook.

Biohit
Analyse af
Antti Siltanen

Biohit: From basics to growth mode

In its recent strategy update for 2024-2028, Biohit said it aims to achieve 15-20% annual growth with an EBIT target of at least 10% of revenue. Compared to our previous forecasts, the targets emphasis growth, with profitability taking a back seat.

Biohit